Brief: Palvella Therapeutics Announces Positive Topline Results From Phase 3 Selva Clinical Study Of Qtorin™
24/02/2026 11:37
Feb 24 (Reuters) - Palvella Therapeutics Inc PVLA.O: PALVELLA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 SELVA CLINICAL STUDY OF QTORIN™ 3.9% RAPAMYCIN ANHYDROUS GEL (QTORIN™ RAPAMYCIN) IN MICROCYSTIC LYMPHATIC MALFORMATIONS PALVELLA THERAPEUTICS INC: PALVELLA PLANS TO SUBMIT A NEW DRUG APPLICATION TO FDA IN SECOND HALF OF 2026 PALVELLA THERAPEUTICS INC - PHASE 3 TRIAL MEETS PRIMARY ENDPOINT WITH SIGNIFICANT IMPROVEMENT PALVELLA THERAPEUTICS INC - QTORIN™ RAPAMYCIN WELL-TOLERATED WITH NO SERIOUS ADVERSE EVENTS PALVELLA - ACHIEVED STATISTICAL SIGNIFICANCE ON PRE-SPECIFIED KEY SECONDARY ENDPOINT (P<0.001) & ALL 4 SECONDARY EFFICACY ENDPOINTS (ALL P<0.001) Source text: ID:nGNX6zqMf0 Further company coverage: PVLA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Palvella Therapeutics
See all newsPalvella Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Palvella Therapeutics Q2 net loss widens on higher expenses
Brief: Palvella Therapeutics Announces New Data From The Phase 2 Toiva Trial Of Qtorin™ Rapamycin In Cutaneous Venous Malformations
Brief: Palvella Therapeutics Announces Uplisting To The Nasdaq Global Market
Palvella Therapeutics' Q1 net loss widens on higher costs